Vesugen (a short synthetic bioregulatory peptide) requires careful reconstitution before subcutaneous injection in research settings. The peptide arrives as a lyophilized powder that must be dissolved in an appropriate solvent. Solvent choice, final pH, and storage temperature all affect peptide stability and biological activity. This article reviews published data and practical formulation principles for Vesugen reconstitution.
Chemical Structure and Source of Vesugen
Vesugen is a synthetic peptide composed of three amino acids: lysine, glutamic acid, and aspartic acid. Its sequence is Lys-Glu-Asp, giving it a molecular weight of approximately 390 Daltons. The peptide was developed at the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson 2017).
Vesugen belongs to a class of short peptides called cytomedins or bioregulators. These peptides are derived from tissue-specific protein complexes. Vesugen specifically originates from blood vessel extracts. The synthetic version mirrors the natural tripeptide sequence found in vascular tissue.
Because Vesugen is so short, it lacks significant secondary structure in solution. This simplifies reconstitution compared to larger peptides like Cerebrolysin (a mixture of neuropeptides). However, the free amino and carboxyl termini make Vesugen sensitive to pH extremes.
Mechanism of Action at the Receptor Level
Vesugen does not bind a classical G protein-coupled receptor. Instead, it appears to interact with DNA-binding proteins and transcription factors after cell entry (Khavinson 2014). Studies show Vesugen can penetrate cell membranes without a carrier. Once inside, it localizes to the nucleus and influences gene expression.
One proposed mechanism involves Vesugen binding to the TATA box region of certain promoters. This interaction may modulate transcription of genes involved in vascular repair. A 2016 study (Khavinson 2016) reported that Vesugen increased expression of VEGF and basic fibroblast growth factor in cultured endothelial cells.
Vesugen also affects the activity of telomerase in some cell types. Telomerase maintains telomere length during cell division. By activating telomerase, Vesugen may delay cellular senescence in vascular endothelium. This pathway is separate from the growth factor effects.
At the systemic level, Vesugen shows weak affinity for angiotensin II receptors. This could explain its mild vasodilatory action in animal models. However, the primary effects are likely genomic rather than receptor-mediated.
Summary of Preclinical and Clinical Research
Most Vesugen research comes from Russian laboratories. A 2013 trial (Khavinson 2013) examined Vesugen in elderly patients with arterial hypertension. The study reported improved endothelial function after a 30-day course. No serious adverse events were noted.
In a 2018 animal study (Anisimov 2018), Vesugen reduced atherosclerotic plaque area in rabbits fed a high-cholesterol diet. The peptide was given subcutaneously at 0.5 mcg per kg body weight. Plaque reduction was 38% compared to control.
Another line of research focuses on retinal vascular disorders. A 2020 paper (Trofimova 2020) described Vesugen effects on diabetic retinopathy in rats. The peptide decreased vascular leakage and normalized capillary density. These results support the vascular repair hypothesis.
Human data remain limited. A 2019 open-label study (Korkushko 2019) included 40 patients with chronic venous insufficiency. Vesugen injections improved venous tone and reduced leg edema. The study lacked a placebo arm, so conclusions are tentative.
Comparative studies with other bioregulators exist. Selank (a synthetic anxiolytic peptide) and Thymosin Alpha-1 (an immune-modulating peptide) have different targets. Vesugen is more specific for vascular tissue. Pentadeca Arginate (a 15-amino acid peptide) shares some angiogenic properties but is structurally unrelated.
Tesamorelin (a growth hormone-releasing hormone analog) also affects vascular health indirectly. However, its mechanism involves the pituitary axis, not direct gene regulation. Vesugen's short sequence makes it unique among these compounds.
Practical Reconstitution Steps and Stability Data
Vesugen is typically supplied as a lyophilized powder in sterile vials. Each vial contains 10 mg of peptide. The powder should be stored at -20°C before reconstitution. Avoid repeated freeze-thaw cycles of the dry powder.
For reconstitution, bacteriostatic water or sterile water for injection is most common. Normal saline (0.9% sodium chloride) can also be used. Some researchers prefer 0.5% acetic acid for highly hydrophobic peptides, but Vesugen is hydrophilic and dissolves readily in water.
To reconstitute, add 1 mL of solvent to the vial. Swirl gently; do not shake vigorously. The peptide should dissolve within 30 seconds. The resulting solution has a concentration of 10 mg/mL. This can be diluted further with sterile saline if needed.
pH of the reconstituted solution matters. Vesugen is stable between pH 5.0 and 7.5. Below pH 4.0, the peptide degrades rapidly via aspartic acid cleavage. Above pH 8.0, deamidation of glutamine residues occurs. Use pH test strips to verify the final solution.
Once reconstituted, Vesugen solution should be used within 24 hours if kept at room temperature. Refrigerated at 4°C, the solution remains stable for up to 7 days. For longer storage, aliquot and freeze at -20°C. Avoid freezing and thawing more than twice.
Cost of Vesugen varies by supplier. A single 10 mg vial costs around $48 from research chemical vendors. A monthly supply at typical research doses (0.1 to 1 mg per injection) runs about $200. Bulk purchases reduce per-vial cost to $35.
Do not mix Vesugen with other peptides in the same syringe. Cerebrolysin, for example, contains multiple peptide fragments that could interact. If multiple injections are needed, use separate syringes and injection sites.
Open Questions and Evidence Gaps
Long-term stability data for reconstituted Vesugen are scarce. Most studies use fresh solutions prepared daily. No published data exist for lyophilized Vesugen stored at room temperature for more than one month.
The optimal solvent for subcutaneous injection remains debated. Water for injection is standard, but some researchers add 0.1% human serum albumin to reduce adsorption to plastic. This practice has not been validated for Vesugen specifically.
Bioavailability after subcutaneous injection is assumed to be high due to the peptide's small size. However, no formal pharmacokinetic study in humans has been published. Animal data suggest a half-life of 20 to 40 minutes.
Interactions with other peptides or medications are unknown. Vesugen may affect blood pressure, so caution is warranted when combined with antihypertensive drugs. No formal drug interaction studies exist.
Finally, the reproducibility of Russian bioregulator research outside that country is limited. Independent replication of key findings would strengthen the evidence base. Until then, Vesugen remains a research compound with promising but preliminary data.
All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.